Surefire Medical Inc.
This article was originally published in Start Up
Executive Summary
Current embolic therapies for cancer have one major drawback. When they're introduced into a vessel through a catheter, reflux often occurs along the catheter, sending the medication backward into another vessel and into non-targeted tissue. The safety of these could greatly improve with Surefire Medical's new embolic therapy catheter. Surefire's initial therapeutic target is liver cancer.
You may also be interested in...
TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.
Start-Up Previews (03/2011)
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Antidepressants: Emerging From Their Funk?," includes profiles of Euthymics Bioscience, Naurex and PharmaNeuroBoost. Plus these Start-Ups Across Health Care: Edge Therapeutics, Ensemble Therapeutics, Magnetecs, Mederi Therapeutics and Surefire Medical.
Advancing Ablative Tumor Therapies Into Primary Treatments
For many cancers, there is a need for a third option between the two current choices of radical tissue destruction and watchful waiting. New cancer ablation devices in development have the potential to fill that gap. Ablative tumor therapies can play a role in eradication of early-stage and localized tumors, as salvage therapies in patients who've failed other therapies, and for patients whose health precludes surgery or further radiation. Ablation has many advantages. It's a cost-effective and minimally invasive alternative to robotic surgery or radiation devices, and may lead to fewer side effects and complications than current primary tumor treatments. But proving that ablation can save lives compared to more radical forms of therapy requires clinical evidence from multiyear outcome trials that few smaller companies are willing to invest in. There's little evidence to date that venture investors will see returns. But the race is on among companies hoping to become the first device approved for low-risk, localized prostate cancer, a potentially game-changing event.